UTMB and HDT Bio receive US funding for vaccine development
Pharmaceutical Technology
NOVEMBER 30, 2022
in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.
Let's personalize your content